NUEC, NuEarth Corp., NUEC.PK
The Finalizing of the Joint Venture Continuation Agreement brings 2 new laboratory projects to TerraSolv. These projects are valued currently valued at more than $1.5 Million over the three-month work schedule starting in October 2010. However, each contact has provisions that could triple the final contact value to more than $6 Million USD over their 12 month life cycle.
“We’ve seen incredible value from the lab, which has paid for itself several times over in its first year of operations. It represents a new, higher standard for doing business in IT throughout the environmental and agricultural industries. We’re taking more risk out of the system, putting more structure into it, suffering less downtime and delivering higher-quality services,” said Levi Modelevi - CEO of NUEC, the parent of TerraSolv SA. The TerraSolv SA Laboratory has generated more than $32 Million over its 3 year existence – Mostly due to the Joint Venture with Laboratorio Internazionale Agricoltura, S/p/A.
NUEC is a company dedicated to bringing to market “Clean Solutions to Complex Problems” by offering a wide range of biodegradable, environmentally friendly products and technologies that will substitute for many of the hazardous chemicals commonly used all over the world.
Last Trade: 0.03
To learn more about NUEC visit: http://www.nuearthcorp.com
CBIS, Cannabis Science, Inc., CBIS.OB
New research establishes 10,000 year old plant helps control pain
The reasons why Cannabis Science is entering the pharmaceutical cannabis industry is that recent advances in science have opened the door to develop, produce, and commercialize, a variety of effective whole plant cannabinoid based pharmaceutical products with a wide variety of important applications.
Although cannabis has been used medicinally for thousands of years, until very recently little was known about how it actually worked.
Synthetic cannabinoids are available as prescription drugs in many countries. Examples include Marinol, available in Germany and the United States, and Cesamet, available in Canada, Mexico, the United Kingdom, and also in the United States.
In each instance a pharmaceutical company controls the drug, and its price, which can make it very expensive. Enter Cannabis Science Inc., and a new day is dawning in the control of chronic pain they are developing not only prescription drugs, but are using medical marijuana in the treatment and control of pain.
Medical Marijuana after a 10,000 year absence has returned to use in the treatment of chronic pain, it should never have left.
Cannabis Science operates with world authorities on phytocannabinoid science which focuses on critical illnesses, and adheres to scientific methodologies in order to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Moreover, they are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
And everyone knows that prescription drugs mean a lot of money.
Last Trade: 0.05
To find out more information visit: http://www.cannabisscience.com
CRWEnewswire is not liable for the contents of this news, as well as not being liable for any errors or delays in the content, or for any actions taken in reliance thereon.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received three thousand five hundred dollars from a third party (Paaga Media) for one (1) day of advertising for NuEarth Corp. (OTCPK:NUEC). Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB)